Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine
- Resource Type
- Authors
- Jessica Nyström; Aril Frydén; Matti Sällberg; Kristina Cardell; Thora Björg Björnsdottir; Catharina Hultgren
- Source
- Vaccine. 26:5967-5972
- Subject
- CD4-Positive T-Lymphocytes
HBsAg
Hepatitis A vaccine
CD8-Positive T-Lymphocytes
medicine.disease_cause
Interferon-gamma
Antigen
Orthohepadnavirus
Humans
Medicine
Hepatitis B Vaccines
Vaccines, Combined
Hepatitis B Antibodies
Hepatitis B virus
Hepatitis A Vaccines
Hepatitis B Surface Antigens
General Veterinary
General Immunology and Microbiology
biology
business.industry
Public Health, Environmental and Occupational Health
virus diseases
Hepatitis A
biology.organism_classification
medicine.disease
Virology
digestive system diseases
Vaccination
Infectious Diseases
Hepadnaviridae
Immunology
Molecular Medicine
business
- Language
- ISSN
- 0264-410X
We successfully re-vaccinated hepatitis B virus (HBV) vaccine non-responders using a double dose of the combined hepatitis A virus (HAV) and HBV vaccine. The hope was to improve priming of hepatitis B surface antigen (HBsAg)-specific cell mediated immune response (CMI) by an increased antigen dose and a theoretical adjuvant-effect from the local presence of a HAV-specific CMI. A few non-responders had a detectable HBsAg-specific CMI before re-vaccination. An in vitro detectable HBsAg-specific CMI was primed equally effective in non-responders (58%) as in first time vaccine recipients (68%). After the third dose a weak, albeit significant, association was observed between the magnitude of HBsAg-specific proliferation and anti-HBs levels. This regimen improves the priming of HBsAg-specific CMIs and antibodies.